A Phase I Study To Evaluate the Safety of Umbilical Cord - Derived, Ex-Vivo Cultured and Expanded Wharton's Jelly Mesenchymal Stem Cells for the Treatment of De Novo High Risk Acute or Steroid Refractory Acute Graft Versus Host Disease
Latest Information Update: 27 Feb 2024
At a glance
- Drugs MSCTC-0010 (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 22 Feb 2024 Planned End Date changed from 1 Aug 2023 to 1 Aug 2025.
- 22 Feb 2024 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2025.
- 30 Jan 2023 Planned primary completion date changed from 1 Aug 2022 to 1 Aug 2023.